Pattern Of Endoscopic Findings In Patients Underwent Upper Endoscopy In Sohag University Hospital

April 6, 2023 updated by: Aya Ahmed Hassan, Sohag University

Diseases associated with upper gastrointestinal tract (UGIT) are common and associated with significant morbidity and mortality globally. Peptic ulcer disease, gastroesophageal reflux disease and cancers affect millions of people worldwide.

Upper endoscopy used for various diagnostic and therapeutic utic indications.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Upper GI symptoms are common complaints among the general population and the underlying diseases associated with them carrey significant morbidit.To the best of our knowledge , there is few data about the prevalence rate of various endoscopic findings among Egyptian ptients with UGI symptoms.

Upper gastrointestinal endoscopy (UGIE) is a valuable tool in the diagnosis and management of diseases affecting the esophagus, stomach and upper parts of the duodenum . In addition to direct inspection of the mucosa, endoscopies can be used for therapeutic interventions. Standard diagnostic indications for UGIE include upper gastrointestinal bleeding, evaluation of persistent epigastric pain despite an appropriate trial of therapy, persistent vomiting, dysphagia, anemia, symptoms or signs suggesting structural disease (e.g., anorexia, weight loss,),new onset dyspepsia in a patient older than 50 years of age, heartburn, oesophageal reflux symptoms that persist or recur despite appropriate therapy, surveillance of malignancy, and screening for oesophageal varices in cirrhotic patients. Therapeutic indications include Esophageal variceal ligation, upper GI bleeding control, foreign body removal, dilation or stenting of strictures, placement of feeding tubes, management of achalasia and endoscopic mucosal resection (EMR).

Study Type

Interventional

Enrollment (Actual)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: all patients underwent upper endoscopy for various indication at endoscopy unit of Tropical Medicine and Gastroenterology Department, Sohag University Hospital during the specified period of the study

-

Exclusion Criteria:

  • Absolute Contraindications

    • Perforated bowel.
    • Peritonitis.
    • Toxic megacolon in an unstable patient. Relative Contraindications
    • Severe neutropenia.
    • Coagulopathy.
    • Severe thrombocytopenia or impaired platelet function.• Increased risk of perforation including connective tissue disorders, recent bowel surgery or bowel obstruction.
    • Aneurysm of the abdominal and iliac aorta

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
spectrum of distribution of endoscopic findings
Time Frame: 2 years
To assess endoscopic findings in patients presented with upper gastrointestinal symptoms
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Actual)

December 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

March 27, 2023

First Submitted That Met QC Criteria

April 6, 2023

First Posted (Actual)

April 19, 2023

Study Record Updates

Last Update Posted (Actual)

April 19, 2023

Last Update Submitted That Met QC Criteria

April 6, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-23-03-04MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe